Abstract
There are several problems associated with the ex ante pricing of new drugs and a key objection is the delay in launching drugs in order to permit cost-effectiveness analysis and set price. The Commitment Process™ provides a transparent and workable methodology for setting price upfront which aligns the interests of both company and assessment authority and confers considerable benefits to both parties. A critical benefit of this process is the removal of any delays in launching new drugs following MHRA authorisation.
Get full access to this article
View all access options for this article.